Literature DB >> 23416860

Advances in the management of biliary tract cancers.

Kristen Keon Ciombor1, Laura Williams Goff.   

Abstract

Biliary tract cancers, although uncommon, are highly fatal malignancies. Current treatments fail to cure or control the majority of tumors. Given the complexity of the anatomy and the often aggressive nature of the disease, multidisciplinary treatment, including palliation, is often required. However, systemic therapy with cytotoxics and/or targeted agents is routinely the mainstay of treatment for patients with advanced biliary tract cancers, and new targets and agents provide hope for this disease. This article focuses on recent advances in the management of biliary tract cancers, with a special focus on the molecular basis for current therapeutic investigation in this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416860      PMCID: PMC3713630     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  49 in total

1.  Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma.

Authors:  K M McMasters; T M Tuttle; S D Leach; T Rich; K R Cleary; D B Evans; S A Curley
Journal:  Am J Surg       Date:  1997-12       Impact factor: 2.565

2.  Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

Authors:  M Penz; G V Kornek; M Raderer; H Ulrich-Pur; W Fiebiger; A Lenauer; D Depisch; G Krauss; B Schneeweiss; W Scheithauer
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

3.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

Authors:  B Glimelius; K Hoffman; P O Sjödén; G Jacobsson; H Sellström; L K Enander; T Linné; C Svensson
Journal:  Ann Oncol       Date:  1996-08       Impact factor: 32.976

4.  Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.

Authors:  M Raderer; M H Hejna; J B Valencak; G V Kornek; G S Weinländer; E Bareck; J Lenauer; T Brodowicz; F Lang; W Scheithauer
Journal:  Oncology       Date:  1999-04       Impact factor: 2.935

5.  Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.

Authors:  David J Rea; Julie K Heimbach; Charles B Rosen; Michael G Haddock; Steven R Alberts; Walter K Kremers; Gregory J Gores; David M Nagorney
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

6.  Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Authors:  Jennifer J Knox; David Hedley; Amit Oza; Ron Feld; Lillian L Siu; Eric Chen; Mahsan Nematollahi; Gregory R Pond; Jessica Zhang; Malcolm J Moore
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.

Authors:  Kumiko Nakazawa; Yoh Dobashi; Shioto Suzuki; Hideki Fujii; Yasuhisa Takeda; Akishi Ooi
Journal:  J Pathol       Date:  2005-07       Impact factor: 7.996

8.  Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.

Authors:  Jong-Sung Park; Sung-Yong Oh; Sung-Hyun Kim; Hyuk-Chan Kwon; Jae-Seok Kim; Hyo Jin-Kim; Young-Hoon Kim
Journal:  Jpn J Clin Oncol       Date:  2005-02       Impact factor: 3.019

9.  Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.

Authors:  Steven R Alberts; Hani Al-Khatib; Michelle R Mahoney; Lawerence Burgart; Peter J Cera; Patrick J Flynn; Tom R Finch; Ralph Levitt; Harold E Windschitl; James A Knost; Loren K Tschetter
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

10.  Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.

Authors:  S Rao; D Cunningham; R E Hawkins; M E Hill; D Smith; F Daniel; P J Ross; J Oates; A R Norman
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

View more
  11 in total

1.  Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform.

Authors:  Priya Gopinathan; Lien-Yu Hung; Chih-Hung Wang; Nai-Jung Chiang; Yu-Chun Wang; Yan-Shen Shan; Gwo-Bin Lee
Journal:  Biomicrofluidics       Date:  2017-07-05       Impact factor: 2.800

Review 2.  Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.

Authors:  Heng Liu; Qi-Di Zhang; Zheng-Hong Li; Qing-Qing Zhang; Lun-Gen Lu
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

3.  pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells.

Authors:  Ju-Il Yang; Hye Lim Lee; Je-Jung Yun; Jungsoo Kim; Kyoung-Ha So; Young-Il Jeong; Dae-Hwan Kang
Journal:  Materials (Basel)       Date:  2022-05-26       Impact factor: 3.748

4.  Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.

Authors:  Kai-Chao Feng; Ye-Lei Guo; Yang Liu; Han-Ren Dai; Yao Wang; Hai-Yan Lv; Jian-Hua Huang; Qing-Ming Yang; Wei-Dong Han
Journal:  J Hematol Oncol       Date:  2017-01-05       Impact factor: 17.388

5.  Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis.

Authors:  Ying Wang; Min Ding; Qian Zhang; Jinghan Wang; Xijing Yang; Fuping Zhou; Linfang Li; Zhengang Yuan; Huajun Jin; Qijun Qian
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

Review 6.  The Emerging Role of miRNAs and Their Clinical Implication in Biliary Tract Cancer.

Authors:  Nina Nayara Ferreira Martins; Kelly Cristina da Silva Oliveira; Amanda Braga Bona; Marília de Arruda Cardoso Smith; Geraldo Ishak; Paulo Pimentel Assumpção; Rommel Rodríguez Burbano; Danielle Queiroz Calcagno
Journal:  Gastroenterol Res Pract       Date:  2016-12-27       Impact factor: 2.260

7.  First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.

Authors:  Hossein Taghizadeh; Matthias Unseld; Andreas Schmiderer; Angela Djanani; Klaus Wilthoner; Dieter Buchinger; Gerald W Prager
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-18       Impact factor: 3.333

8.  Bioactive constituents isolated from Atractylodes lancea (Thunb.) DC. rhizome exhibit synergistic effect against cholangiocarcinoma cell.

Authors:  Pongsakorn Martviset; Wanna Chaijaroenkul; Phunuch Muhamad; Kesara Na-Bangchang
Journal:  J Exp Pharmacol       Date:  2018-10-25

9.  Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells.

Authors:  Tae Won Kwak; Do Hyung Kim; Young-Il Jeong; Dae Hwan Kang
Journal:  J Nanobiotechnology       Date:  2015-09-26       Impact factor: 10.435

Review 10.  Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.

Authors:  Noomi Vainer; Christian Dehlendorff; Julia S Johansen
Journal:  Oncotarget       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.